WEI HU to Neoplasm Staging
This is a "connection" page, showing publications WEI HU has written about Neoplasm Staging.
Connection Strength
0.008
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7.
Score: 0.005
-
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res. 1998 Jun; 4(6):1383-91.
Score: 0.003